According to Rigel Pharmaceuticals's latest financial reports the company's current EPS (TTM) is -$0.38. In 2022 the company made an earnings per share (EPS) of -$0.59 a decrease over its 2021 EPS that were of -$0.17.
Year | EPS | Change |
---|---|---|
2023 (TTM) | -$0.37 | -36.92% |
2022 | -$0.59 | 240% |
2021 | -$0.17 | -37.5% |
2020 | -$0.28 | -60% |
2019 | -$0.69 | -11.11% |
2018 | -$0.77 | -26.23% |
2017 | -$1.05 | -17.57% |
2016 | -$1.27 | 25.42% |
2015 | -$1.02 | -42.72% |
2014 | -$1.77 | 1.98% |
2013 | -$1.74 | -24.06% |
2012 | -$2.29 | -4.32% |
2011 | -$2.39 | -290.41% |
2010 | $1.26 | -126.64% |
2009 | -$4.72 | -25.14% |
2008 | -$6.30 | 41.86% |
2007 | -$4.44 | 70.86% |
2006 | -$2.60 | -27.4% |
2005 | -$3.58 | -33.33% |
2004 | -$5.37 | -37.73% |
2003 | -$8.63 | -31.83% |
2002 | -$12.66 | -63.55% |
2001 | -$34.72 | -96.43% |
2000 | -$973.40 |